Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PEC-Encap
- Development stage
- Discontinued
- Lead developer
- Vertex
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Subcutaneous
01
Overview
PEC‑Encap is an encapsulated human pancreatic progenitor cell therapy developed by ViaCyte (now a subsidiary of Vertex Pharmaceuticals). The product consists of stem cell-derived pancreatic progenitor cells (PEC‑01) loaded into the Encaptra drug delivery system, which acts as an immunoprotective device. When implanted subcutaneously, the encapsulated cells are designed to mature into functional pancreatic endocrine cells—including insulin-producing beta cells—potentially providing a source of endogenous insulin for patients with type 1 diabetes. The encapsulation aims to protect the transplanted cells from immune rejection, eliminating or reducing the need for immunosuppression. Clinical development has focused on type 1 diabetes mellitus; however, challenges with engraftment and efficacy have led to trial terminations and discontinuation of further development[1][4][5][6][7].
- Brand names
- PEC EncapVC-01VC01VC 01
- Other names
- Encapsulated human islet cell therapy - ViaCyteEncapsulated pancreatic cell transplantation therapy - ViaCyteEncapsulated islet cell transplantation therapy - ViaCytePEC-EnCap™VC‑01 Combination Product
Beyond the preview
Go deeper on PEC-Encap.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PEC-Encap.